Asthma control and exacerbations in patients with severe asthma treated with omalizumab in Portugal

Sousa, Ana; Pereira, Ana Margarida; Fonseca, João; Azevedo, Luís Filipe; Abreu, Carmo; Arrobas, Ana; Calvo, Teresa; Silvestre, Maria José; Cunha, Liliana; Falcão, Helena; Drummond, Marta; Geraldes, L.; Loureiro, Carla Chaves

doi:10.1016/j.rppnen.2015.03.002

Cited by 10 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody approved in the European Union (EU) as an add-on therapy to improve asthma control in patients aged C 6 years with severe persistent allergic asthma [4]. The efficacy of omalizumab in improving asthma control has been documented in several studies [5,6], including the 5-year Evaluating Clinical Effectiveness and Long-term Safety (EXCELS) in patients with moderate-to-severe asthma observational study [7]. Asthma control can be measured by means of the asthma control questionnaire (ACQ)-6, which is a shortened, six-item variant of the ACQ proper, but excludes the lung function assessment domain.…”

Section: Introductionmentioning

confidence: 99%

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

2019

View full text Add to dashboard Cite

Introduction: Allergic asthma is a chronic inflammatory disease caused by immunoglobulin E (IgE)-mediated allergy. Omalizumab is a monoclonal anti-IgE antibody for the treatment of severe allergic asthma (SAA). Objectives: The primary objective of the study was to assess asthma-related control in patients with SAA receiving omalizumab therapy. Secondary objectives included quality of life, treatment effectiveness, rate of severe exacerbations, and safety. Methods: This was a prospective, multi-centre, non-interventional study to assess patient-related long-term outcomes of omalizumab treatment in Germany. This 3-year study

show abstract

Section: Introductionmentioning

confidence: 99%

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

2019

View full text Add to dashboard Cite

show abstract

“…The authors also reported that there was a 49% reduction in the number of steroid courses per patient per annum [63]. In uncontrolled severe persistent allergic asthmatic patients with frequent exacerbations observed for 1 year, omalizumab reduced the dose of OCS from 10.6 mg/day to 6.2 mg/day [72].…”

Section: Omalizumabmentioning

confidence: 98%

Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence

Calzetta

Aiello

Frizzelli

et al. 2021

IJMS

View full text Add to dashboard Cite

Airway inflammation represents an important characteristic in asthma, modulating airflow limitation and symptom control, and triggering the risk of asthma exacerbation. Thus, although corticosteroids represent the cornerstone for the treatment of asthma, severe patients may be dependent on oral corticosteroids (OCSs). Fortunately, the current humanised monoclonal antibodies (mAbs) benralizumab, dupilumab, mepolizumab, omalizumab, and reslizumab have been proven to induce an OCS-sparing effect in randomized controlled trials (RCTs), thus overcoming the problem of OCS dependence in severe asthma. Nevertheless, a large discrepancy has been recognized between selected patients enrolled in RCTs and non-selected asthmatic populations in real-world settings. It is not possible to exclude that the OCS-sparing effect of mAbs resulting from the RCTs could be different than the real effect resulting in clinical practice. Therefore, we performed a systematic review and correlation analysis to assess whether mAbs are effective in eliciting an OCS-sparing effect and overcoming the OCS dependence in severe asthmatic patients in real-world settings. Overall, real-world studies support the evidence that OCS dependence is a real condition that, however, can be found only in a small number of really severe asthmatic patients. In most patients, the dependence on OCS can be related to modifying factors that, when adequately modulated, may lead to a significant reduction or suspension of OCS maintenance. Conversely, in severe asthmatics in whom OCS resistance is proved by a high daily dose intake, mAbs allow reversion of the OCS dependence, leading to the suspension of OCS therapy in most patients or >50% reduction in the daily OCS dose.

show abstract

“…CARAT has been implemented in different settings (pharmacies, primary care, secondary care, epidemiology and clinical research) and technologies including mHealth tools, 17,42,45,47,48,[51][52][53] but also in severe asthma by specialists. 54…”

Section: Validationmentioning

confidence: 99%

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice

Bousquet

Antó

Bachert

et al. 2020

Allergy

View full text Add to dashboard Cite

show abstract

Asthma control and exacerbations in patients with severe asthma treated with omalizumab in Portugal

Cited by 10 publications

References 21 publications

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study

Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice

Contact Info

Product

Resources

About